Top

Published in:

Open Access 01-12-2013 | Research article

Herpes zoster surveillance using electronic databases in the Valencian Community (Spain)

Authors: Nuria Morant-Talamante, Javier Diez-Domingo, Sergio Martínez-Úbeda, Joan Puig-Barberá, Sara Alemán-Sánchez, Lina Pérez-Breva

Published in: BMC Infectious Diseases | Issue 1/2013

Abstract

Background

Epidemiologic data of Herpes Zoster (HZ) disease in Spain are scarce. The objective of this study was to assess the epidemiology of HZ in the Valencian Community (Spain), using outpatient and hospital electronic health databases.

Methods

Data from 2007 to 2010 was collected from computerized health databases of a population of around 5 million inhabitants. Diagnoses were recorded by physicians using the International Classification of Diseases, 9th Revision, Clinical Modification (ICD-9-CM). A sample of medical records under different criteria was reviewed by a general practitioner, to assess the reliability of codification.

Results

The average annual incidence of HZ was 4.60 per 1000 persons-year (PY) for all ages (95% CI: 4.57-4.63), is more frequent in women [5.32/1000PY (95% CI: 5.28-5.37)] and is strongly age-related, with a peak incidence at 70-79 years. A total of 7.16/1000 cases of HZ required hospitalization.

Conclusions

Electronic health database used in the Valencian Community is a reliable electronic surveillance tool for HZ disease and will be useful to define trends in disease burden before and after HZ vaccine introduction.

Available only for authorised users

Johnson RW: Herpes zoster and postherpetic neuralgia. Expert Rev Vaccines. 2010, 9 (3 Suppl): 21-26.CrossRefPubMed

Johnson RW, McElhaney J: Postherpetic neuralgia in the elderly. Int J Clin Pract. 2009, 63 (9): 1386-1391. 10.1111/j.1742-1241.2009.02089.x.CrossRefPubMedPubMedCentral

Drolet M, Brisson M, Schmader KE, Levin MJ, Johnson R, Oxman MN, et al: The impact of herpes zoster and postherpetic neuralgia on health-related quality of life: a prospective study. CMAJ. 2010, 182 (16): 1731-1736. 10.1503/cmaj.091711.CrossRefPubMedPubMedCentral

Dworkin RH, Gnann JW, Oaklander AL, Raja SN, Schmader KE, Whitley RJ: Diagnosis and assessment of pain associated with herpes zoster and postherpetic neuralgia. J Pain. 2008, 9 (1 Suppl 1): S37-S44.CrossRefPubMed

Drolet M, Levin MJ, Schmader KE, Johnson R, Oxman MN, Patrick D, et al: Employment related productivity loss associated with herpes zoster and postherpetic neuralgia: a 6-month prospective study. Vaccine. 2012, 30 (12): 2047-2050. 10.1016/j.vaccine.2012.01.045.CrossRefPubMed

Lukas K, Edte A, Bertrand I: The impact of herpes zoster and post-herpetic neuralgia on quality of life: patient-reported outcomes in six European countries. Z Gesundh Wiss. 2012, 20 (4): 441-451. 10.1007/s10389-011-0481-8.CrossRefPubMed

Plotkin SAOW, Offit PA: Vaccines. 2008, Philadelphia: Saunders Elsevier, 5

Yawn BP, Saddier P, Wollan PC, St Sauver JL, Kurland MJ, Sy LS: A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction. Mayo Clin Proc. 2007, 82 (11): 1341-1349. 10.4065/82.11.1341.CrossRefPubMed

Drolet M, Oxman MN, Levin MJ, Schmader KE, Johnson RW, Patrick D, et al: Vaccination against herpes zoster in developed countries: state of the evidence. Hum Vaccin Immunother. 2013, 9 (5): 1177-1184. 10.4161/hv.23491.CrossRefPubMedPubMedCentral

10.

Schmader K: Herpes zoster in older adults. Clin Infect Dis. 2001, 32 (10): 1481-6. 10.1086/320169.CrossRefPubMed

11.

Pinchinat S, Cebrián-Cuenca AM, Bricout H, Johnson RW: Similar herpes zoster incidence across Europe: results from a systematic literature review. BMC Infect Dis. 2013, 13: 170-10.1186/1471-2334-13-170.CrossRefPubMedPubMedCentral

12.

Thomas SL, Hall AJ: What does epidemiology tell us about risk factors for herpes zoster?. Lancet Infect Dis. 2004, 4 (1): 26-33. 10.1016/S1473-3099(03)00857-0.CrossRefPubMed

13.

European Commission: Europe’s demographic future: Facts and figures on challenges and opportunities. 2012, Directorate-General for Employment, Social Affairs and Equal Opportunities, http://ec.europa.eu/social/BlobServlet?docId=1540%26langId=en,

14.

Aw D, Silva AB, Palmer DB: Immunosenescence: emerging challenges for an ageing population. Immunology. 2007, 120 (4): 435-46. 10.1111/j.1365-2567.2007.02555.x.CrossRefPubMedPubMedCentral

15.

Salleras M, Domínguez A, Soldevila N, Prat A, Garrido P, Torner N, et al: Contacts with children and young people and adult risk of suffering herpes zoster. Vaccine. 2011, 29 (44): 7602-5. 10.1016/j.vaccine.2011.08.023.CrossRefPubMed

16.

Thomas SL, Wheeler JG, Hall AJ: Contacts with varicella or with children and protection against herpes zoster in adults: a case-control study. Lancet. 2002, 360 (9334): 678-82. 10.1016/S0140-6736(02)09837-9.CrossRefPubMed

17.

Yih WK, Brooks DR, Lett SM, Jumaan AO, Zhang Z, Clements KM, et al: The incidence of varicella and herpes zoster in Massachusetts as measured by the behavioral risk factor surveillance system (BRFSS) during a period of increasing varicella vaccine coverage, 1998-2003. BMC Public Health. 2005, 5: 68-10.1186/1471-2458-5-68.CrossRefPubMedPubMedCentral

18.

Guzzetta G, Poletti P, Del Fava E, Ajelli M, Scalia Tomba GP, Merler S, et al: Hope-Simpson’s progressive immunity hypothesis as a possible explanation for herpes zoster incidence data. Am J Epidemiol. 2013, 177 (10): 1134-42. 10.1093/aje/kws370.CrossRefPubMed

19.

Bennett GJ, Watson CP: Herpes zoster and postherpetic neuralgia: past, present and future. Pain Res Manag. 2009, 14 (4): 275-82.CrossRefPubMedPubMedCentral

20.

Karhunen M, Leino T, Salo H, Davidkin I, Kilpi T, Auranen K: Modelling the impact of varicella vaccination on varicella and zoster. Epidemiol Infect. 2010, 138 (4): 469-81. 10.1017/S0950268809990768.CrossRefPubMed

21.

Brisson M, Gay NJ, Edmunds WJ, Andrews NJ: Exposure to varicella boosts immunity to herpes-zoster: implications for mass vaccination against chickenpox. Vaccine. 2002, 20 (19–20): 2500-7.CrossRefPubMed

22.

van Hoek AJ, Melegaro A, Zagheni E, Edmunds WJ, Gay N: Modelling the impact of a combined varicella and zoster vaccination programme on the epidemiology of varicella zoster virus in England. Vaccine. 2011, 29 (13): 2411-20. 10.1016/j.vaccine.2011.01.037.CrossRefPubMed

23.

Gao Z, Gidding HF, Wood JG, MacIntyre CR: Modelling the impact of one-dose vs. two-dose vaccination regimens on the epidemiology of varicella zoster virus in Australia. Epidemiol Infect. 2010, 138 (4): 457-68. 10.1017/S0950268809990860.CrossRefPubMed

24.

Gaillat J, Gajdos V, Launay O, Malvy D, Demoures B, Lewden L, et al: Does monastic life predispose to the risk of Saint Anthony’s fire (herpes zoster)?. Clin Infect Dis. 2011, 53 (5): 405-10. 10.1093/cid/cir436.CrossRefPubMed

25.

Poletti P, Melegaro A, Ajelli M, Del Fava E, Guzzetta G, Faustini L, et al: Perspectives on the impact of varicella immunization on herpes zoster. A model-based evaluation from three European countries. PLoS One. 2013, 8 (4): e60732-10.1371/journal.pone.0060732.CrossRefPubMedPubMedCentral

26.

Jumaan AO, Yu O, Jackson LA, Bohlke K, Galil K, Seward JF: Incidence of herpes zoster, before and after varicella-vaccination-associated decreases in the incidence of varicella, 1992-2002. J Infect Dis. 2005, 191 (12): 2002-7. 10.1086/430325.CrossRefPubMed

27.

Asociación Española de Pediatría: Documento en relación al calendario único de vacunaciones y las vacunas disponibles en España. 2013, http://vacunasaep.org/sites/vacunasaep.org/files/AEP-vacunas-y-calendario-vacunal-unico_0.pdf,

28.

Oxman MN, Levin MJ, Johnson GR, Schmader KE, Straus SE, Gelb LD, et al: A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med. 2005, 352 (22): 2271-84. 10.1056/NEJMoa051016.CrossRefPubMed

29.

Schmader KE, Levin MJ, Gnann JW, McNeil SA, Vesikari T, Betts RF, et al: Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50-59 years. Clin Infect Dis. 2012, 54 (7): 922-8. 10.1093/cid/cir970.CrossRefPubMedPubMedCentral

30.

Langan SM, Smeeth L, Margolis DJ, Thomas SL: Herpes zoster vaccine effectiveness against incident herpes zoster and post-herpetic neuralgia in an older US population: a cohort study. PLoS Med. 2013, 10 (4): e1001420-10.1371/journal.pmed.1001420.CrossRefPubMedPubMedCentral

31.

European Medicines Agency: European Public Assessment Report (EPAR) for ZOSTAVAX summary of product characteristics. 2012, http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000674/WC500053462.pdf,

32.

Study to Evaluate GSK Biologicals’ Herpes Zoster Vaccine GSK1437173A in Adults Aged >= 70 Years: ClinicalTrails.gov. 2012, http://clinicaltrials.gov/ct2/show/NCT01165229?term=zoster%26rank=1,

33.

Study to Evaluate GSK Biologicals’ Herpes Zoster Vaccine GSK1437173A in Adults Aged >= 50 Years: ClinicalTrials.gov. 2012, http://clinicaltrials.gov/ct2/show/NCT01165177?term=zoster%26rank=14,

34.

Leroux-Roels I, Leroux-Roels G, Clement F, Vandepapelière P, Vassilev V, Ledent E, et al: A phase 1/2 clinical trial evaluating safety and immunogenicity of a varicella zoster glycoprotein e subunit vaccine candidate in young and older adults. J Infect Dis. 2012, 206 (8): 1280-90. 10.1093/infdis/jis497.CrossRefPubMed

35.

Cebrián-Cuenca AM, Díez-Domingo J, Rodríguez MS, Puig-Barberá J, Navarro-Pérez J: Community’ HZRGotV. Epidemiology of herpes zoster infection among patients treated in primary care centres in the Valencian community (Spain). BMC Fam Pract. 2010, 11: 33-10.1186/1471-2296-11-33.CrossRefPubMedPubMedCentral

36.

Cebrián-Cuenca AM, Díez-Domingo J, San-Martín-Rodríguez M, Puig-Barberá J, Navarro-Pérez J: Community HZRGotV. Epidemiology and cost of herpes zoster and postherpetic neuralgia among patients treated in primary care centres in the Valencian community of Spain. BMC Infect Dis. 2011, 11: 302-10.1186/1471-2334-11-302.CrossRefPubMedPubMedCentral

37.

Instituto Nacional de Estadística: Cifras oficiales de población resultantes de la revisión del Padrón municipal a 1 de enero de 2011. 2012, http://www.ine.es/jaxi/tabla.do?path=/t20/e260/a2011/l0/%26file=ccaa01.px%26type=pcaxis%26L=0,

38.

Indra Sistemas SA: Proyecto Abucasis Conselleria Sanitat Valencia. 2012, http://www.indracompany.com/sectores/sanidad/proyectos/179/proyecto-abucasis-conselleria-de-sanitat-valencia,

39.

España. Ministerio de Sanidad y Política Social: Las TIC en el Sistema Nacional de Salud : el programa Sanidad en línea: actualización de datos enero 2010. 2010, Madrid: Red.es, 24-Available from: http://www.msssi.gob.es/profesionales/hcdsns/TICS/TICS_SNS_ACTUALIZACION_ES_2010.pdf

40.

Puig-Barberà J, Natividad-Sancho A, Calabuig-Pérez J, Lluch-Rodrigo JA, Pastor-Villalba E, Martínez-Úbeda S, et al: MF59-adjuvanted and virosomal influenza vaccines for preventing influenza hospitalization in older people: comparative effectiveness using the Valencia health care information system. Vaccine. 2013, 31: 3995-4002. 10.1016/j.vaccine.2013.05.070.CrossRefPubMed

41.

Gil A, Gil R, Alvaro A, San Martín M, González A: Burden of herpes zoster requiring hospitalization in Spain during a seven-year period (1998-2004). BMC Infect Dis. 2009, 9: 55-10.1186/1471-2334-9-55.CrossRefPubMedPubMedCentral

42.

García Cenoz M, Castilla J, Montes Y, Morán J, Salaberri A, Elía F, et al: Varicella and herpes zoster incidence prior to the introduction of systematic child vaccination in Navarre, 2005-2006. An Sist Sanit Navar. 2008, 31 (1): 71-80.CrossRefPubMed

43.

Pérez-Farinós N, Ordobás M, García-Fernández C, García-Comas L, Cañellas S, Rodero I, et al: Varicella and herpes zoster in Madrid, based on the sentinel general practitioner network: 1997-2004. BMC Infect Dis. 2007, 7: 59-10.1186/1471-2334-7-59.CrossRefPubMedPubMedCentral

44.

Gil A, San-Martín M, Carrasco P, González A: Epidemiology of severe varicella-zoster virus infection in Spain. Vaccine. 2004, 22 (29–30): 3947-3951.CrossRefPubMed

45.

Peña-Rey I, de Aragón MV M, Villaverde Hueso A, Terres Arellano M, Alcalde Cabero E, Suárez Rodríguez B: [Epidemiology of varicella in spain pre-and post-vaccination periods]. Rev Esp Salud Publica. 2009, 83 (5): 711-24. 10.1590/S1135-57272009000500012.CrossRefPubMed

46.

Chiappe SG, Sarazin M, Turbelin C, Lasserre A, Pelat C, Bonmarin I, et al: Herpes zoster: Burden of disease in France. Vaccine. 2010, 28 (50): 7933-8. 10.1016/j.vaccine.2010.09.074.CrossRef

47.

Gialloreti LE, Merito M, Pezzotti P, Naldi L, Gatti A, Beillat M, et al: Epidemiology and economic burden of herpes zoster and post-herpetic neuralgia in Italy: a retrospective, population-based study. BMC Infect Dis. 2010, 10: 230-10.1186/1471-2334-10-230.CrossRefPubMedPubMedCentral

48.

de Melker H, Berbers G, Hahné S, Rümke H, van den Hof S, de Wit A, et al: The epidemiology of varicella and herpes zoster in The Netherlands: implications for varicella zoster virus vaccination. Vaccine. 2006, 24 (18): 3946-52. 10.1016/j.vaccine.2006.02.017.CrossRefPubMed

49.

Ultsch B, Siedler A, Rieck T, Reinhold T, Krause G, Wichmann O: Herpes zoster in Germany: quantifying the burden of disease. BMC Infect Dis. 2011, 11: 173-10.1186/1471-2334-11-173.CrossRefPubMedPubMedCentral

50.

Leung J, Harpaz R, Molinari NA, Jumaan A, Zhou F: Herpes zoster incidence among insured persons in the United States, 1993-2006: evaluation of impact of varicella vaccination. Clin Infect Dis. 2011, 52 (3): 332-40. 10.1093/cid/ciq077.CrossRefPubMed

51.

Tseng HF, Smith N, Harpaz R, Bialek SR, Sy LS, Jacobsen SJ: Herpes zoster vaccine in older adults and the risk of subsequent herpes zoster disease. JAMA. 2011, 305 (2): 160-6. 10.1001/jama.2010.1983.CrossRefPubMed

52.

Oxman MN: Herpes zoster pathogenesis and cell-mediated immunity and immunosenescence. J Am Osteopath Assoc. 2009, 109 (6 Suppl 2): S13-7.PubMed

53.

Hope-Simpson RE: The Nature of Herpes Zoster: A long-term study and a new hypothesis. Proc R Soc Med. 1965, 58: 9-20.PubMedPubMedCentral

54.

van Lier A, van Hoek AJ, Opstelten W, Boot HJ, de Melker HE: Assessing the potential effects and cost-effectiveness of programmatic herpes zoster vaccination of elderly in the Netherlands. BMC Health Serv Res. 2010, 10: 237-10.1186/1472-6963-10-237.CrossRefPubMedPubMedCentral

55.

Bilcke J, Ogunjimi B, Marais C, de Smet F, Callens M, Callaert K, et al: The health and economic burden of chickenpox and herpes zoster in Belgium. Epidemiol Infect. 2012, 140 (11): 2096-109. 10.1017/S0950268811002640.CrossRefPubMed

56.

Scott FT, Johnson RW, Leedham-Green M, Davies E, Edmunds WJ, Breuer J: The burden of Herpes Zoster: a prospective population based study. Vaccine. 2006, 24 (9): 1308-14. 10.1016/j.vaccine.2005.09.026.CrossRefPubMed

The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2334/13/463/prepub

Title: Herpes zoster surveillance using electronic databases in the Valencian Community (Spain)
Authors: Nuria Morant-Talamante
Javier Diez-Domingo
Sergio Martínez-Úbeda
Joan Puig-Barberá
Sara Alemán-Sánchez
Lina Pérez-Breva
Publication date: 01-12-2013
Publisher: BioMed Central
Published in: BMC Infectious Diseases / Issue 1/2013
Electronic ISSN: 1471-2334
DOI: https://doi.org/10.1186/1471-2334-13-463

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2013

Brain localization of Kaposi’s sarcoma in a patient treated by combination antiretroviral therapy

Mycobacterium abscessus isolated from municipal water - a potential source of human infection

The effect of dams and seasons on malaria incidence and anopheles abundance in Ethiopia

Impact of a tenofovir disoproxil fumarate plus ritonavir-boosted protease inhibitor-based regimen on renal function in HIV-infected individuals: a prospective, multicenter study

Frequency and antimicrobial resistance patterns of bacteria implicated in community urinary tract infections: a ten-year surveillance study (2000–2009)

Report of a pertussis outbreak in a low coverage booster vaccination group of otherwise healthy children in Italy

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage